Skip to content

News Category: Health & Medical

TauRx Announces Additional Investment of USD119 million following announcement of Phase 3 LUCIDITY Topline Results

By asianet

– Substantial investment of USD119 million achieved by TauRx through a warrants exercise triggered by the announcement of LUCIDITY results in October, supporting HMTM regulatory submissions in UK, US and Canada, and preparation for market availability – Shareholder commitment to TauRx represents a significant success story for UK-based life sciences research and development in areas … Continued

LOTUS REPORTS ITS BEST QUARTER EVER WITH THE BIGGEST LAUNCH IN ITS HISTORY

By asianet

Lotus Pharmaceutical (1795: TT), a multinational pharmaceutical company, today reported its financial results for the third quarter ended 30 September 2022. Third quarter financial highlights: – Third quarter 2022 is the best quarter ever in the Company’s history, majorly driven by the successful launch of Lenalidomide in the US – the biggest launch in Lotus … Continued

TES Pharma Congratulates Intercept Pharmaceuticals on their Presentation of Phase 1 INT-787 Data at the AASLD Meeting and the Initiation of the Phase 2a FRESH Study in Patients with Severe Alcohol-Associated Hepatitis

By asianet

INT-787 is a selective next generation FXR agonist invented by TES Pharma and licensed to Intercept Pharmaceuticals INT-787 has shown strong anti-fibrotic and anti-inflammatory effects in animal models TES Pharma is dedicated to the identification of novel therapeutic targets and the discovery and development of new molecules to efficiently address the needs of patients with … Continued

Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster

By asianet

— The Novavax BA.1 vaccine candidate met its primary strain-change endpoint allowing for development of variant vaccines, if necessary — Novavax’ prototype vaccine induced broad immune response against original Wuhan, BA.1, and BA.5 strains — The trial showed no benefit for a bivalent vaccine utilizing Novavax’ recombinant protein/adjuvant technology Novavax, Inc. (Nasdaq: NVAX), a biotechnology … Continued

EIT Health’s Venture Centre of Excellence Names ProductLife Group as Privileged Partner for Regulatory & Compliance

By asianet

– The ambitious EU initiative has already secured 2 billion euros of co-investment capabilities and has supported 60 innovative Biotech, Medtech & digital health start-ups to get to market or expand into new territories. – EIT Health, co-operator of the Venture Centre of Excellence alongside the European Investment Fund (EIF), has named ProductLife Group the … Continued

OMRON Declares Its Commitment to Doubling Energy Productivity by 2040 to Achieve Carbon Neutrality, Becoming Japan’s First Manufacturing Company to Join EP100

By asianet

OMRON Corporation headquartered in Shimogyo-ku, Kyoto, became a member of The Climate Group’s “EP100” (*1) initiatives. OMRON is the first Japanese company in the manufacturing industry and the fourth Japanese company in general to join the EP100 initiative, which brings together over 120 energy smart businesses committed to measuring and reporting on energy efficiency improvements. … Continued

Turn Biotechnologies Names 25-year Biotech Industry Veteran Richard Peterson Chief Financial Officer

By asianet

— Seasoned Executive has Successful Track Record Working with Global Investors to Raise Billions of Dollars Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced it has appointed Richard “Ric” Peterson as chief financial officer. Photo – https://mma.prnewswire.com/media/1935041/Turn_Biotechnologies_Ric_Peterson.jpg Logo – https://mma.prnewswire.com/media/1935529/TURN_LOGO_HI_RES_Logo.jpg Mr. Peterson, who has served as … Continued

NCCN Working with Medlive to Advance High-Quality Cancer Care in China and Worldwide

By asianet

–United States-based National Comprehensive Cancer Network enters strategic cooperation agreement with Chinese medical information website to publish and translate evidence-based expert consensus guidelines for cancer care; now available at nccnchina.org.cn ( https://c212.net/c/link/?t=0&l=en&o=3691705-1&h=1106361729&u=http%3A%2F%2Fwww.nccnchina.org.cn&a=nccnchina.org.cn ). The National Comprehensive Cancer Network(R) (NCCN ( https://c212.net/c/link/?t=0&l=en&o=3691705-1&h=769424173&u=http%3A%2F%2Fwww.nccn.org%2F&a=NCCN )(R))-an alliance of leading cancer centers ( https://c212.net/c/link/?t=0&l=en&o=3691705-1&h=3644457603&u=https%3A%2F%2Fwww.nccn.org%2Fhome%2Fmember-institutions&a=leading+cancer+centers ) in the United States-is announcing … Continued

Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis

By asianet

Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group (“Menarini”), a privately-held, leading international pharmaceutical company, today announced that the European Commission (EC) has granted orphan medicinal product designation for selinexor for the treatment of myelofibrosis (MF). Selinexor was granted orphan drug designation in MF by the … Continued

Pervistop[R], the once-daily supplement specifically designed to manage persistent HPV, is now available for exclusive distribution rights worldwide.

By asianet

– Lo.Li. Pharma International to unveil an innovative new product at CPHI Frankfurt, which has already gained the interest of numerous distribution partners. Pervistop[R] promises to be an extremely effective tool in the management of an exceedingly unpredictable disease. Lo.Li. Pharma International announces the pre-launch of a new, highly anticipated product at CPHI 2022, fulfilling … Continued